Literature DB >> 9817111

Methods for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. International Quality of Life Assessment.

J E Ware1, B Gandek.   

Abstract

Following the translation development stage, the second research stage of the IQOLA Project tests the assumptions underlying item scoring and scale construction. This article provides detailed information on the research methods used by the IQOLA Project to evaluate data quality, scaling and scoring assumptions, and the reliability of the SF-36 scales. Tests include evaluation of item and scale-level descriptive statistics; examination of the equality of item-scale correlations, item internal consistency and item discriminant validity; and estimation of scale score reliability using internal consistency and test-retest methods. Results from these tests are used to determine if standard algorithms for the construction and scoring of the eight SF-36 scales can be used in each country and to provide information that can be used in translation improvement.

Mesh:

Year:  1998        PMID: 9817111     DOI: 10.1016/s0895-4356(98)00085-7

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  181 in total

1.  A community-based study of scaling assumptions and construct validity of the English (UK) and Chinese (HK) SF-36 in Singapore.

Authors:  J Thumboo; K Y Fong; D Machin; S P Chan; K H Leon; P H Feng; S T Thio; M L Boe
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

2.  Validation of a quality-of-life scale for women with bladder pain syndrome/interstitial cystitis.

Authors:  Laura M Bogart; Marika J Suttorp; Marc N Elliott; J Quentin Clemens; Sandra H Berry
Journal:  Qual Life Res       Date:  2011-12-07       Impact factor: 4.147

3.  Reliability and validity of the SF-36 in HIV-infected homeless and marginally housed individuals.

Authors:  E D Riley; D R Bangsberg; S Perry; R A Clark; A R Moss; A W Wu
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

4.  The equivalence of English and Chinese SF-36 versions in bilingual Singapore Chinese.

Authors:  Julian Thumboo; Kok-Yong Fong; Siew-Pang Chan; David Machin; Pao-Hsii Feng; Szu-Tien Thio; Mee-Leng Boey
Journal:  Qual Life Res       Date:  2002-08       Impact factor: 4.147

5.  Validation of the KDQOL-SF: a dialysis-targeted health measure.

Authors:  J C Korevaar; M P Merkus; M A M Jansen; F W Dekker; E W Boeschoten; R T Krediet
Journal:  Qual Life Res       Date:  2002-08       Impact factor: 4.147

6.  Performance of the Swedish SF-36 version 2.0.

Authors:  Charles Taft; Jan Karlsson; Marianne Sullivan
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

7.  Cross-cultural evaluation of the French version of the LEIPAD, a health-related quality of life instrument for use in the elderly living at home.

Authors:  I Jalenques; C Auclair; J Roblin; D Morand; R Tourtauchaux; R May; E Vaille-Perret; J Watts; L Gerbaud; D De Leo
Journal:  Qual Life Res       Date:  2012-04-03       Impact factor: 4.147

Review 8.  Health related quality of life measures in Arabic speaking populations: a systematic review on cross-cultural adaptation and measurement properties.

Authors:  Fatima Al Sayah; Sana Ishaque; Darren Lau; Jeffrey A Johnson
Journal:  Qual Life Res       Date:  2012-02-18       Impact factor: 4.147

9.  Cross-Cultural Validation of the Patient Perception of Integrated Care Survey.

Authors:  Maike V Tietschert; Federica Angeli; Arno J A van Raak; Dirk Ruwaard; Sara J Singer
Journal:  Health Serv Res       Date:  2017-07-20       Impact factor: 3.402

10.  The MOVES (Motor tic, Obsessions and compulsions, Vocal tic Evaluation Survey): cross-cultural evaluation of the French version and additional psychometric assessment.

Authors:  Isabelle Jalenques; Candy Guiguet-Auclair; Philippe Derost; Pauline Joubert; Louis Foures; Andreas Hartmann; Julia Muellner; Fabien Rondepierre
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.